Stockscreener 앱 받기
2.19
2.82%
0.06
시간 외 거래:
2.10
-0.09
-4.11%
BiomX Inc 주식(PHGE)의 최신 뉴스
Is BiomX Inc a good long term investmentBullish Engulfing Patterns & Minimal Investment Capital - earlytimes.in
Is BiomX Inc. stock a buy before product launchesJobs Report & Target Return Focused Stock Picks - DonanımHaber
How interest rate cuts could boost BiomX Inc. stockEarnings Growth Report & High Conviction Investment Ideas - DonanımHaber
Is BiomX Inc. stock resilient to inflationTrade Risk Summary & Weekly Top Performers Watchlists - DonanımHaber
Is BiomX Inc. stock recession proofEarnings Growth Report & Consistent Growth Stock Picks - DonanımHaber
Will BiomX Inc. stock outperform foreign stocksJuly 2025 Reactions & High Win Rate Trade Alerts - DonanımHaber
Is BiomX Inc. stock oversold or undervalued2025 Big Picture & Consistent Growth Stock Picks - DonanımHaber
BiomX (NYSEAMERICAN:PHGE) Shares Up 9.9% – Still a Buy? - Defense World
What risks investors should watch in BiomX Inc. stockPortfolio Risk Report & AI Enhanced Trading Alerts - DonanımHaber
Is BiomX Inc. stock ready for breakoutJuly 2025 Recap & Accurate Entry and Exit Point Alerts - Улправда
Market Rankings: Can BiomX Inc. stock reach $100 price targetJuly 2025 EndofMonth & Safe Entry Zone Tips - ulpravda.ru
BiomX collapses into court proceedings after clinical trial fails - CTech
BIOMX INCDECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMC - 富途牛牛
BiomX Discontinues Study and Files for Insolvency - TipRanks
BiomX Inc. Discontinues Phase 2b Study and Initiates Insolvency Proceedings - TradingView — Track All Markets
BiomX (NYSE: PHGE) subsidiary seeks insolvency as Phase 2b study ends, BX011 program retained - Stock Titan
BiomX Discontinues Phase 2b Trial for BX004 - The Globe and Mail
Earnings Beat: Is BiomX Inc stock oversold or undervaluedJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - moha.gov.vn
Healthy Upside Potential: BiomX Inc (PHGE) - setenews.com
BiomX Halts Phase 2b Trial Of BX004 In Cystic Fibrosis On High Rates Of Adverse Events - Nasdaq
Stocks Tumble As Bad News Hits Biotech And Energy Sectors - Finimize
BiomX Discontinues Phase 2b Clinical Trial for BX004 - TradingView — Track All Markets
BiomX (PHGE) Halts Phase 2b Trial and Implements Cost-Saving Str - GuruFocus
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review - The Manila Times
BiomX announces discontinuation of phase 2b Bx004 trial following internal review - marketscreener.com
BiomX discontinues phase 2b trial for BX004 - MSN
BiomX (PHGE) Price Target Increased by 964.52% to 168.30 - Nasdaq
BiomX (PHGE) Stock Analysis Report | Financials & Insights - Benzinga
Why BiomX Inc. stock could be top winner2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
How BiomX Inc. stock performs in high volatility marketsJuly 2025 Update & Daily Price Action Insights - Newser
How BiomX Inc. stock reacts to Fed tighteningJuly 2025 Update & AI Forecasted Entry/Exit Points - Newser
How BiomX Inc. stock compares with tech leadersJuly 2025 Review & Technical Pattern Alert System - Newser
How forex fluctuations impact BiomX Inc. stockWeekly Stock Recap & High Yield Equity Trading Tips - Newser
Is BiomX Inc. stock ideal for retirement investorsMarket Growth Report & Comprehensive Market Scan Reports - Newser
How BiomX Inc. stock behaves in tightening cyclesAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
BiomX provides update on BX004 Phase 2b trial in Cystic Fibrosis - MSN
BiomX announces 1-for-19 reverse stock split - MSN
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries - Investing.com Canada
BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
HC Wainwright Issues Optimistic Estimate for BiomX Earnings - Defense World
BiomX (NYSEAMERICAN:PHGE) Price Target Raised to $26.00 at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for BiomX (NYSEAMERICAN:PHGE) Stock - Defense World
HC Wainwright Boosts BiomX (NYSEAMERICAN:PHGE) Price Target to $26.00 - Defense World
HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation - Nasdaq
PHGE: HC Wainwright & Co. Reiterates Buy Rating with $26 PT | PH - GuruFocus
Why Is BiomX Stock Falling Today?BiomX (AMEX:PHGE) - Benzinga
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Sahm
BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 - Nasdaq
BiomX Says Working to Lift FDA Hold Concerning Nebulizer Device in Phase 2b Study of BX004 for Cystic Fibrosis - marketscreener.com
FDA Review Delays BiomX's (PHGE) Cystic Fibrosis Trial Progress - GuruFocus
BiomX Updates on Phase 2b Study for BX004 - TipRanks
BiomX Updates on FDA Clinical Hold and Study Progress - TradingView
BiomX (NYSE American: PHGE) DMC Backs BX004 Phase 2b Study, Topline Expected 2026 - Stock Titan
PHGE: HC Wainwright Raises Price Target for BiomX to $26.00 | PH - GuruFocus
HC Wainwright & Co. Maintains BiomX (PHGE) Buy Recommendation - Nasdaq
0.67%
1.93%
자본화:
|
볼륨(24시간):